Pliant Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Pliant Therapeutics (Nasdaq: PLRX), a clinical-stage biotechnology firm, announced that its President and CEO, Bernard Coulie, will participate in two investor conferences in May 2022. The RBC Capital Markets Global Healthcare conference will feature a fireside chat on May 18 at 10:00 a.m. ET, while a replay of the H.C. Wainwright Global Investment Conference chat will be available on May 23 at 7:00 a.m. ET. Interested parties can access these events on Pliant's Investor Relations page.

SOUTH SAN FRANCISCO, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D., Pliant’s President and Chief Executive Officer, will participate in the following May investor conferences.

• 2022 RBC Capital Markets Global Healthcare: Dr. Coulie will participate in a fireside chat on Wednesday, May 18, at 10:00 a.m. ET / 7:00 a.m. PT
• H.C. Wainwright Global Investment Conference: Dr. Coulie will participate in a fireside chat, the replay of which will be available Monday, May 23, at 7:00 a.m. ET

Interested parties can access these fireside chats from the Investor Relations’ Events & Presentation page of Pliant’s website at https://ir.pliantrx.com/news-and-events/events-and-presentations with an audio archive available for 30 days from the time they are made available.

About Pliant Therapeutics, Inc.

Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small molecule dual selective inhibitor of α_vß₆ and α_vß₁ integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Fast Track Designation and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in IPF and Orphan Drug Designation from the FDA and European Medicines Agency in PSC. Pliant is currently conducting Phase 2a trials of PLN-74809 in the lead indications of IPF and PSC. Pliant has also developed PLN-1474, a small molecule selective inhibitor of α_vß₁ for the treatment of nonalcoholic steatohepatitis, or NASH with liver fibrosis, which Pliant has transferred to Novartis pursuant to our development partnership. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies. For additional information about Pliant Therapeutics, visit www.pliantrx.com and follow us on Twitter, LinkedIn, Facebook and YouTube.

Investor and Media Contact:

Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
ir@pliantrx.com

 

FAQ

What is Pliant Therapeutics' stock symbol?

Pliant Therapeutics is listed under the stock symbol PLRX.

When will Bernard Coulie speak at the RBC Capital Markets Global Healthcare conference?

Bernard Coulie will speak on May 18, 2022, at 10:00 a.m. ET.

How can I access the H.C. Wainwright Global Investment Conference replay?

The replay will be available on May 23, 2022, at 7:00 a.m. ET on Pliant's Investor Relations page.

What is the focus of Pliant Therapeutics?

Pliant Therapeutics focuses on developing novel therapeutics for the treatment of fibrosis.

What is PLN-74809 and its significance?

PLN-74809 is Pliant's lead product candidate, aimed at treating idiopathic pulmonary fibrosis and has received Fast Track and Orphan Drug Designations.